Table 3.
Variable | Reference | Multivariate analysis | |
---|---|---|---|
HR (95%CI) | p value | ||
Treatment: NAC | PCS | 2.33 (1.66–3.28) | < 0.001 |
Age at diagnosis > 50 yr | ≤ 50 yr | 1.12 (0.79–1.57) | 0.53 |
Suboptimal debulking status | Optimal | 1.61 (1.14–2.26) | 0.007 |
Resistant to platinum-based chemotherapy* | Sensitive | — | — |
Cycles of primary chemotherapy > 6 | ≤ 6 | 0.96 (0.69–1.34) | 0.82 |
CI = confidence interval, HR = hazard ratio; NAC = neoadjuvant chemotherapy and interval cytoreductive surgery; PCS = primary cytoreductive surgery and adjuvant chemotherapy.
Sensitivity to platinum-based chemotherapy has nonproportional hazard. It was included in the multivariate analysis as a stratification factor.